A Phase 1, Randomized, Double-blind, Crossover Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of QEV-817 Oral Suspension in Healthy Volunteers

This study has been designed to assess the safety, tolerability, and pharmacokinetics of a therapeutic dose of hydrocodone bitartrate with and without an oral dose of doxapram hydrochloride in healthy volunteers who are naltrexone-blocked.

开始日期2024-09-01

申办/合作机构

Quivive Pharma, Inc.初创企业

[+1]

ACTRN12621001163897 / Recruiting临床2期IIT

Oral Doxapram for Apnoea of Prematurity: Dosage Study in Preterm Infants

开始日期2022-02-28

申办/合作机构

Auckland University

IRCT20200825048515N51 / Recruiting临床3期IIT

Comparative study of the effect of caffeine and doxapram on respiratory parameters of patients admitted to intensive care units after spinal surgery

开始日期2022-02-04

申办/合作机构

Isfahan University of Medical Sciences

100 项与盐酸多沙普仑相关的临床结果

登录后查看更多信息

100 项与盐酸多沙普仑相关的转化医学

登录后查看更多信息

100 项与盐酸多沙普仑相关的专利（医药）

登录后查看更多信息

559

项与盐酸多沙普仑相关的文献（医药）

2024-11-01·Journal of Comparative Physiology A

The effects of doxapram and its potential interactions with K2P channels in experimental model preparations

Article

作者: Brock, Kaitlyn E ; Vacassenno, Rachael M ; Harrison, Douglas A ; Elliott, Elizabeth R ; Cooper, Robin L

The channels commonly responsible for maintaining cell resting membrane potentials are referred to as K2P (two-P-domain K⁺ subunit) channels. These K⁺ ion channels generally remain open but can be modulated by their local environment. These channels are classified based on pharmacology, pH sensitivity, mechanical stretch, and ionic permeability. Little is known about the physiological nature of these K2P channels in invertebrates. Acidic conditions depolarize neurons and muscle fibers, which may be caused by K2P channels given that one subtype can be blocked by acidic conditions. Doxapram is used clinically as a respiratory aid known to block acid-sensitive K2P channels; thus, the effects of doxapram on the muscle fibers and synaptic transmission in larval Drosophila and crawfish were monitored. A dose-dependent response was observed via depolarization of the larval Drosophila muscle and an increase in evoked synaptic transmission, but doxapram blocked the production of action potentials in the crawfish motor neuron and had a minor effect on the resting membrane potential of the crawfish muscle. This indicates that the nerve and muscle tissues in larval Drosophila and crawfish likely express different K2P channel subtypes. Since these organisms serve as physiological models for neurobiology and physiology, it would be of interest to further investigate what types of K2P channel are expressed in these tissues. (212 words).

2024-07-01·Archives of Disease in Childhood - Fetal and Neonatal Edition

Doxapram for apnoea of prematurity and neurodevelopmental outcomes at age 5–6 years

Article

作者: Onland, Wes ; Benhammou, Valérie ; Letouzey, Mathilde ; Kuhn, Pierre ; Tréluyer, Ludovic ; Pierrat, Véronique ; Marchand-Martin, Laetitia ; Zana-Taieb, Elodie ; Ancel, Pierre Yves ; Saade, Lauren ; Torchin, Héloïse ; Jarreau, Pierre-Henri

ObjectiveTo assess the long-term neurodevelopmental impact of doxapram for treating apnoea of prematurity.DesignSecondary analysis of the French national cohort study EPIPAGE-2. Recruitment took place in 2011. A standardised neurodevelopmental assessment was performed at age 5–6 years. A 2:1 propensity score matching was used to control for the non-randomised assignment of doxapram treatment.SettingPopulation-based cohort study.PatientsAll children born before 32 weeks’ gestation alive at age 5–6 years.InterventionsBlind and standardised assessment by trained neuropsychologists and paediatricians at age 5–6 years.Main outcome measuresNeurodevelopmental outcomes at age 5–6 years assessed by trained paediatricians and neuropsychologists: cerebral palsy, developmental coordination disorders, IQ and behavioural difficulties. A composite criterion for overall neurodevelopmental disabilities was built.ResultsThe population consisted of 2950 children; 275 (8.6%) received doxapram. Median (IQR) gestational age was 29.4 (27.6–30.9) weeks. At age 5–6 years, complete neurodevelopmental assessment was available for 60.3% (1780 of 2950) of children and partial assessment for 10.6% (314 of 2950). In the initial sample, children receiving doxapram had evidence of greater clinical severity than those not treated. Doxapram treatment was associated with overall neurodevelopmental disabilities of any severity (OR 1.43, 95% CI 1.07 to 1.92, p=0.02). Eight hundred and twenty-one children were included in the 2:1 matched sample. In this sample, perinatal characteristics of both groups were similar and doxapram treatment was not associated with overall neurodevelopmental disabilities (OR 1.09, 95% CI 0.76 to 1.57, p=0.63).ConclusionsIn children born before 32 weeks’ gestation, doxapram treatment for apnoea of prematurity was not associated with neurodevelopmental disabilities.

2023-11-01·Journal of Veterinary Pharmacology and Therapeutics

The effect of doxapram on survival and APGAR score in newborn puppies delivered by elective caesarean: A randomized controlled trial

Article

作者: Kordzakhia, Nino ; Hyndman, Timothy H ; Bowden, Ross S ; Irons, Peter C ; Coaicetto, Flaminia ; Page, Stephen W ; Mosing, Martina ; Fretwell, Shelby ; Musk, Gabrielle C ; Tuke, S Jonathan ; Metcalfe, Steven S ; Aleri, Joshua W

AbstractDoxapram is marketed as a respiratory stimulant and is used by some veterinarians to help with neonatal apnoea, especially in puppies delivered by caesarean. There is a lack of consensus as to whether the drug is effective and data on its safety are limited. Doxapram was compared to placebo (saline) in newborn puppies in a randomized, double‐blinded clinical trial using two outcome measures: 7‐day mortality rate and repeated APGAR score measurements. Higher APGAR scores have been positively correlated with survival and other health outcomes in newborns. Puppies were delivered by caesarean and a baseline APGAR score was measured. This was immediately followed by a randomly allocated intralingual injection of either doxapram or isotonic saline (of the same volume). Injection volumes were determined by the weight of the puppy and each injection was administered within a minute of birth. The mean dose of doxapram administered was 10.65 mg/kg. APGAR scores were measured again at 2, 5, 10 and 20 min. One hundred and seventy‐one puppies from 45 elective caesareans were recruited into this study. Five out of 85 puppies died after receiving saline and 7 out of 86 died after receiving doxapram. Adjusting for the baseline APGAR score, the age of the mother and whether the puppy was a brachycephalic breed, there was insufficient evidence to conclude a difference in the odds of 7‐day survival for puppies that received doxapram compared to those that received saline (p = .634). Adjusting for the baseline APGAR score, the weight of the mother, the litter size, the mother's parity number, the weight of the puppy and whether the puppy was a brachycephalic breed, there was insufficient evidence to conclude a difference in the probability of a puppy having an APGAR score of ten (the maximum APGAR score) between those that received doxapram compared to those that received saline (p = .631). Being a brachycephalic breed was not associated with an increased odds of 7‐day mortality (p = .156) but the effect of the baseline APGAR score on the probability of having an APGAR score of ten was higher for brachycephalic than non‐brachycephalic breeds (p = .01). There was insufficient evidence that intralingual doxapram provided an advantage (or disadvantage) compared to intralingual saline when used routinely in puppies delivered by elective caesarean and that were not apnoeic.

项与盐酸多沙普仑相关的新闻（医药）

2024-10-20

·信狐药迅

一线疗法！正大天晴「安罗替尼」新适应症提交上市申请|新受理（10.14-10.20）

本周药品注册受理数据，分门别类呈现，一目了然。(10.14-10.20）新药上市申请药品名称企业注册分类受理号盐酸安罗替尼胶囊正大天晴药业集团股份有限公司2.4CXHS2400108盐酸安罗替尼胶囊正大天晴药业集团股份有限公司2.4CXHS2400107盐酸安罗替尼胶囊正大天晴药业集团股份有限公司2.4CXHS2400106注射用维迪西妥单抗荣昌生物制药(烟台)股份有限公司2.2CXSS2400111 新药临床申请药品名称企业注册分类受理号WJB001胶囊微境生物医药科技(上海)有限公司1CXHL2401115WJB001胶囊微境生物医药科技(上海)有限公司1CXHL2401114ART101注射液苏州昂拓生物医药有限公司1CXHL2401113AK-1286片上海璎黎药业有限公司1CXHL2401112AK-1286片上海璎黎药业有限公司1CXHL2401111LKR202注射液上海利康瑞生物工程有限公司1CXHL2401110盐酸吉卡昔替尼片苏州泽璟生物制药股份有限公司1CXHL2401109CS231295片深圳微芯药业有限责任公司1CXHL2401108CS231295片深圳微芯药业有限责任公司1CXHL2401107CS231295片深圳微芯药业有限责任公司1CXHL2401105ZX-7101A干混悬剂南京征祥医药有限公司1CXHL2401103G201-Na胶囊石家庄以岭药业股份有限公司1CXHL2401102G201-Na胶囊石家庄以岭药业股份有限公司1CXHL2401101H002胶囊泰州红云制药有限公司1CXHL2401095盐酸吉卡昔替尼片上海泽璟医药技术有限公司1CXHL2401094PZH2109胶囊漳州片仔癀药业股份有限公司1CXHL2401089PZH2109胶囊漳州片仔癀药业股份有限公司1CXHL2401088PZH2109胶囊漳州片仔癀药业股份有限公司1CXHL2401087HJ787软膏成都华健未来科技有限公司1CXHL2401086HJ787软膏成都华健未来科技有限公司1CXHL2401085TollB-001片北京拓领博泰生物科技有限公司1CXHL2401084TollB-001片北京拓领博泰生物科技有限公司1CXHL2401083PD-DP-008凝胶成都佩德生物医药有限公司1CXHL2401082HDM1005注射液杭州中美华东制药有限公司1CXHL2401093HDM1005注射液杭州中美华东制药有限公司1CXHL2401092TQH3906胶囊正大天晴药业集团南京顺欣制药有限公司1CXHL2401074TQH3906胶囊正大天晴药业集团南京顺欣制药有限公司1CXHL2401073注射用DYX116江苏德源药业股份有限公司1CXHL2401072注射用DYX116江苏德源药业股份有限公司1CXHL2401071XNW29016片山东信诺维医药科技有限公司1CXHL2401070XNW29016片山东信诺维医药科技有限公司1CXHL2401069HEC169584胶囊广东东阳光药业股份有限公司1CXHL2401068HEC169584胶囊广东东阳光药业股份有限公司1CXHL2401067HEC169584胶囊广东东阳光药业股份有限公司1CXHL2401066HRS-6768注射液天津恒瑞医药有限公司1CXHL2401065HQ2231百诚医药(珠海横琴)有限公司2.2CXHL2401106BCM851口溶膜上海云晟研新生物科技有限公司2.2CXHL2401099BCM851口溶膜上海云晟研新生物科技有限公司2.2CXHL2401098BCM851口溶膜上海云晟研新生物科技有限公司2.2CXHL2401097BCM851口溶膜上海云晟研新生物科技有限公司2.2CXHL2401096SXF-100上海欣峰制药有限公司2.2CXHL2401091司美格鲁肽注射液浙江普洛康裕制药有限公司2.2CXHL2401081司美格鲁肽注射液浙江普洛康裕制药有限公司2.2CXHL2401080司美格鲁肽注射液浙江普洛康裕制药有限公司2.2CXHL2401079司美格鲁肽注射液浙江普洛康裕制药有限公司2.2CXHL2401078司美格鲁肽注射液浙江普洛康裕制药有限公司2.2CXHL2401077司美格鲁肽注射液浙江普洛康裕制药有限公司2.2CXHL2401076司美格鲁肽注射液浙江普洛康裕制药有限公司2.2CXHL2401075KK-R002安徽康正康仁药业有限公司2.3CXHL2401104奥美沙坦酯左氨氯地平片北京福元医药股份有限公司2.3CXHL2401090注射用多西他赛(白蛋白结合型)石药集团中奇制药技术(石家庄)有限公司2.4CXHL2401100重组呼吸道合胞病毒疫苗(CHO细胞)怡道生物科技(苏州)有限公司1.3CXSL2400711注射用ZG005苏州泽璟生物制药股份有限公司1CXSL2400713TJ037130注射液天境生物科技(杭州)有限公司1CXSL2400710GSK4381562A注射液葛兰素史克(中国)投资有限公司1CXSL2400709重组人源化抗表皮生长因子受体单抗注射液上海津曼特生物科技有限公司1CXSL2400712RC1416注射液南京融捷康生物科技有限公司1CXSL2400702注射用Zilovertamab vedotin默沙东研发(中国)有限公司1CXSL2400708重组红细胞生成刺激蛋白注射液(CHO细胞)沈阳三生制药有限责任公司1CXSL2400705注射用MK-6204四川科伦博泰生物医药股份有限公司1CXSL2400707SYS6043石药集团巨石生物制药有限公司1CXSL2400704注射用ZG005苏州泽璟生物制药股份有限公司1CXSL2400700CD-001注射液乘典(苏州)生物医药有限公司1CXSL2400701RC1416注射液南京融捷康生物科技有限公司1CXSL2400703重组人源化抗表皮生长因子受体单抗注射液上海津曼特生物科技有限公司1CXSL2400706CM559注射液康诺亚生物医药科技(成都)有限公司1CXSL2400697SHR-1819注射液广东恒瑞医药有限公司1CXSL2400696IBI3005信达生物制药(苏州)有限公司1CXSL2400699RGB-5088胰岛细胞注射液杭州瑞普晨创科技有限公司1CXSL2400698GNC-038四特异性抗体注射液成都百利多特生物药业有限责任公司1CXSL2400693GNC-038四特异性抗体注射液成都百利多特生物药业有限责任公司1CXSL2400694YFQLXB-UC01注射液山东省齐鲁细胞治疗工程技术有限公司1CXSL2400695 仿制药申请药品名称企业注册分类受理号中长链脂肪乳/氨基酸(16)/葡萄糖(36%)注射液辽宁海思科制药有限公司3CYHS2403541注射用硫酸多黏菌素B广州艾奇西新药研究有限公司3CYHS2403540碳酸氢钠林格注射液(I)海南爱科制药有限公司3CYHS2403539匹伐他汀钙口崩片广东万泰科创药业有限公司3CYHS2403538匹伐他汀钙口崩片广东万泰科创药业有限公司3CYHS2403537匹伐他汀钙口崩片广东万泰科创药业有限公司3CYHS2403536硫糖铝口服混悬液济南同路医药科技发展有限公司3CYHS2403535布美他尼注射液辰欣药业股份有限公司3CYHS2403533碳酸氢钠林格注射液四川太平洋药业有限责任公司3CYHS2403529聚乙二醇3350散浙江远力健药业有限责任公司3CYHS2403528盐酸甲氧氯普胺注射液成都华宇制药有限公司3CYHS2403526盐酸溴己新注射液漯河市汇创医药有限公司3CYHS2403525盐酸文拉法辛缓释片复星医药(徐州)有限公司3CYHS2403508左氧氟沙星注射液重庆药友制药有限责任公司3CYHS2403507维生素B??注射液广州仁恒医药科技股份有限公司3CYHS2403517盐酸甲氧氯普胺注射液扬州中宝药业股份有限公司3CYHS2403516注射用乳糖酸红霉素广东粤和泽药物研究有限公司3CYHS2403502盐酸多沙普仑注射液石家庄四药有限公司3CYHS2403501氨己烯酸口服溶液用散上海上药信谊药厂有限公司3CYHS2403515维生素B6注射液江苏润恒制药有限公司3CYHS2403488阿仑膦酸钠口服溶液海南斯达制药有限公司3CYHS2403492美沙拉秦肠溶缓释颗粒北京福元医药股份有限公司3CYHS2403486美沙拉秦肠溶缓释颗粒北京福元医药股份有限公司3CYHS2403485注射用氢化可的松琥珀酸钠海南紫程众投生物科技有限公司3CYHS2403482盐酸溴己新注射液以岭万洲国际制药有限公司3CYHS2403484复方聚乙二醇(3350)电解质散海南普利制药股份有限公司3CYHS2403470注射用苯唑西林钠湖南柏齐鹤药物研发有限公司3CYHS2403469复方聚乙二醇(3350)电解质散海南普利制药股份有限公司3CYHS2403468氯化钾口服溶液山东百诺医药股份有限公司3CYHS2403457福多司坦口服溶液海南斯达制药有限公司3CYHS2403456福多司坦口服溶液海南斯达制药有限公司3CYHS2403455福多司坦口服溶液海南斯达制药有限公司3CYHS2403454碳酸氢钠注射液黑龙江省知润药业有限公司3CYHS2403453注射用氢化可的松琥珀酸钠重庆万霖生物医药科技有限公司3CYHS2403475注射用氢化可的松琥珀酸钠重庆万霖生物医药科技有限公司3CYHS2403474复方电解质醋酸钠葡萄糖注射液石家庄四药有限公司3CYHS2403450复方电解质醋酸钠葡萄糖注射液石家庄四药有限公司3CYHS2403449聚乙二醇3350散马应龙药业集团股份有限公司3CYHS2403471盐酸溴己新注射液白云山东泰商丘药业有限公司3CYHS2403464利那洛肽胶囊湖北民康药业集团有限公司4CYHS2403534小儿法罗培南钠颗粒珠海前列药业有限公司4CYHS2403532雌二醇片/雌二醇地屈孕酮片复合包装四川科伦药业股份有限公司4CYHS2403531雌二醇片/雌二醇地屈孕酮片复合包装四川科伦药业股份有限公司4CYHS2403530非布司他片四川新斯顿制药股份有限公司4CYHS2403527司来帕格片湖南方盛制药股份有限公司4CYHS2403524马立巴韦片桂林南药股份有限公司4CYHS2403523他克莫司缓释胶囊上海安必生制药技术有限公司4CYHS2403522他克莫司缓释胶囊上海安必生制药技术有限公司4CYHS2403521氨氯地平阿托伐他汀钙片翎耀生物科技(上海)有限公司4CYHS2403520阿卡波糖片上海现代制药股份有限公司4CYHS2403513阿卡波糖片上海现代制药股份有限公司4CYHS2403512格列齐特缓释片南京易亨制药有限公司4CYHS2403511西甲硅油乳剂浙江佰奥医药科技有限公司4CYHS2403510缬沙坦氢氯噻嗪片深圳奥萨制药有限公司4CYHS2403509磷霉素氨丁三醇颗粒湖北午时医药研究院有限公司4CYHS2403519阿司匹林肠溶片长春海悦药业股份有限公司4CYHS2403506克立硼罗软膏苏州高迈药业有限公司4CYHS2403518盐酸屈他维林注射液江苏润恒制药有限公司4CYHS2403505醋酸去氨加压素片苏州第三制药厂有限责任公司4CYHS2403504醋酸去氨加压素片苏州第三制药厂有限责任公司4CYHS2403503注射用伏立康唑悦康药业集团股份有限公司4CYHS2403514依折麦布片翎耀生物科技(上海)有限公司4CYHS2403500氯雷他定糖浆拜耳医药(上海)有限公司4CYHS2403499氯雷他定糖浆拜耳医药(上海)有限公司4CYHS2403498甲磺酸倍他司汀片浙江仙琚制药股份有限公司4CYHS2403497乌帕替尼缓释片杨凌科森生物制药有限责任公司4CYHS2403496非那雄胺片广州艾格生物科技有限公司4CYHS2403495非那雄胺片广州艾格生物科技有限公司4CYHS2403494注射用多种维生素(12)辽宁海思科制药有限公司4CYHS2403493双氯芬酸钠缓释片四川依科制药有限公司4CYHS2403491阿法骨化醇软胶囊大连美创药业有限公司4CYHS2403490阿法骨化醇软胶囊大连美创药业有限公司4CYHS2403489恩替卡韦片浙江麒正药业有限公司4CYHS2403487复方电解质注射液湖北津药药业股份有限公司4CYHS2403483阿达帕林凝胶浙江高跖医药科技股份有限公司4CYHS2403481注射用醋酸西曲瑞克常州四药制药有限公司4CYHS2403480洛索洛芬钠贴剂金鸿药业股份有限公司4CYHS2403479洛索洛芬钠贴剂金鸿药业股份有限公司4CYHS2403478恩他卡朋片山东新华制药股份有限公司4CYHS2403452瑞舒伐他汀依折麦布片(I)南京海纳制药有限公司4CYHS2403451艾普拉唑肠溶片石家庄科仁医药科技有限公司4CYHS2403477聚乙烯醇滴眼液圣嘉(滨海)生物医药科技有限公司4CYHS2403476盐酸伊立替康脂质体注射液浙江智达药业有限公司4CYHS2403473结构脂肪乳注射液(C6-24)广东嘉博制药有限公司4CYHS2403472利丙双卡因乳膏安徽四环科宝制药有限公司4CYHS2403467布瑞哌唑片扬子江药业集团南京海陵药业有限公司4CYHS2403466头孢丙烯片华北制药河北华民药业有限责任公司4CYHS2403463左卡尼汀口服溶液南京恒道医药科技股份有限公司4CYHS2403462地屈孕酮片株洲千金药业股份有限公司4CYHS2403459硝酸异山梨酯注射液云南药科院生物医药股份有限公司4CYHS2403458氨甲环酸片浙江兄弟药业有限公司4CYHS2403465富马酸比索洛尔片成都欣捷高新技术开发股份有限公司4CYHS2403461富马酸比索洛尔片成都欣捷高新技术开发股份有限公司4CYHS2403460冻干人用狂犬病疫苗(鸡胚成纤维细胞)上海青赛生物科技股份有限公司3.3CXSS2400113冻干人用狂犬病疫苗(人二倍体细胞)安徽智飞龙科马生物制药有限公司3.3CXSS2400112尿素[13C]片呼气试验药盒成都倍特药业股份有限公司3CYHL2400204麦芽酚铁胶囊杭州仟源保灵药业有限公司3CYHL2400203瑞卢戈利片杭州民生药业股份有限公司3CYHL2400202利多卡因丙胺卡因气雾剂江西汇仁药业股份有限公司3CYHL2400201他替瑞林片成都简则医药技术有限公司3CYHL2400200 进口申请药品名称企业注册分类受理号Aficamten片Cytokinetics, Incorporated1JXHS2400085多烯磷脂酰胆碱注射液Opella Healthcare Limited Liability Company5.1JXHS2400086卡泊三醇倍他米松泡沫剂LEO Pharma A/S5.1JXHS2400087塞利尼索片Karyopharm Therapeutics Inc.5.1JXHS2400084Tremelimumab注射液AstraZeneca AB3.1JXSS2400099度伐利尤单抗注射液AstraZeneca UK Limited3.1JXSS2400096度伐利尤单抗注射液AstraZeneca UK Limited3.1JXSS2400098Tremelimumab注射液AstraZeneca AB3.1JXSS2400097注射用sotaterceptMerck Sharp & Dohme LLC3.1JXSS2400095注射用sotaterceptMerck Sharp & Dohme LLC3.1JXSS2400094依西美坦片Zydus Lifesciences Limited5.2JYHS2400048Orforglipron胶囊Eli Lilly and Company1JXHL2400254Orforglipron胶囊Eli Lilly and Company1JXHL2400253Orforglipron胶囊Eli Lilly and Company1JXHL2400252Orforglipron胶囊Eli Lilly and Company1JXHL2400251Orforglipron胶囊Eli Lilly and Company1JXHL2400250Orforglipron胶囊Eli Lilly and Company1JXHL2400249Bepirovirsen 注射液GlaxoSmithKline Trading Services Limited1JXHL2400246Daplusiran/Tomligisiran 注射液GlaxoSmithKline Trading Services Limited1JXHL2400245依尼碘铵片JSC“FARMAK”5.1JXHL2400248普拉曲沙注射液Ideogen AG5.1JXHL2400247Belrestotug注射液GlaxoSmithKline Research & Development Limited1JXSL2400196ABBV-400注射用粉末AbbVie Inc.1JXSL2400194注射用BudigalimabAbbVie Inc.1JXSL2400195Dostarlimab注射液GlaxoSmithKline Research & Development Limited2.2JXSL2400197 中药相关申请无注：绿色字体部分为潜在首仿品种；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

申请上市

2023-03-14

·蒲公英Ouryao

参比制剂目录（第65批）正式发布！

‍‍‍‍转自：国家药监局编辑：wangxinglai20042023年03月14日，国家药监局发布了第65批次仿制药一致性评价参比制剂目录，其中新增品种67个、变更及增加持证商品种21个。通知原文经国家药品监督管理局仿制药质量和疗效一致性评价专家委员会审核确定，现发布仿制药参比制剂目录（第六十五批）。涉及品种：非那雄胺片、阿伐替尼片、布美他尼片、尼索地平缓释片、盐酸地尔硫卓缓释胶囊、吲哚美辛搽剂、雌二醇醋酸炔诺酮片、利伐沙班口崩片、低钙腹膜透析液（乳酸盐-G1.5%）、低钙腹膜透析液（乳酸盐-G2.5%）、注射用头孢唑肟钠、普伐他汀钠片、马来酸噻吗洛尔滴眼液、孟鲁司特钠咀嚼片、氯沙坦钾氢氯噻嗪片、卡波姆滴眼液、氯化镭[223Ra]注射液、注射用硫酸艾沙康唑、琥珀酰明胶电解质醋酸钠注射液、普拉左米星注射液、注射用盐酸曲拉西利、克拉考特酮乳膏、富马酸伊布利特注射液、木聚硫钠胶囊、米拉贝隆缓释干混悬剂、硫酸艾沙康唑胶囊、醋酸地非法林注射液、盐酸赛洛唑啉鼻用喷雾剂、盐酸多沙普仑注射液、聚乙烯醇滴眼液、丙酸交沙霉素糖浆剂、甲苯磺酸妥舒沙星片、布地奈德缓释胶囊、曲安奈德鼻喷雾剂、盐酸他喷他多片、氯化钾缓释胶囊、恩格列净利格列汀片、硫酸镁钠钾口服用浓溶液、盐酸奥昔布宁缓释片、二甲双胍恩格列净片等；仿制药参比制剂目录（第65批）（扫描二维码下载附件）仿制药参比制剂目录（第65批）‍‍

一致性评价

2023-01-07

·蒲公英Ouryao

89个品种新增挂网、公示期截止1月10日！

转自：江苏省公共资源中心编辑：wangxinglai20042023年01月06日，江苏省公共资源中心发布了《关于公示药品阳光采购拟挂网产品的通知》，本次涉及89个产品，公示期为2023年1月6日至1月10日。通知原文各相关药品生产企业：根据《江苏省医疗保障局关于深入推进药品阳光采购的实施意见》（苏医保发〔2021〕64号）、《关于公示药品阳光挂网产品的函》（苏价采中心药函〔2023〕2号、苏价采中心药函〔2023〕3号）的要求，已按相关程序进行了审核与确认，现将药品阳光采购拟挂网产品予以公示，共89个品种，具体包括：注射用异环磷酰胺、注射用盐酸多沙普仑、妥布霉素吸入溶液、注射用右雷佐生、注射用头孢米诺钠、阿立哌唑口崩片、曲安奈德口腔软膏、钆喷酸葡胺注射液、复方布洛芬片、降脂灵颗粒、小儿化痰止咳颗粒等；公示期为2023年1月6日至1月10日17：00。如有异议，企业须在公示期内通过江苏省公共资源交易平台（药品分类采购-其他-阳光挂网采购申诉（202301-1））进行申诉，并提交相关证明材料。

带量采购

100 项与盐酸多沙普仑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01872	盐酸多沙普仑	R07AB01	DB00561

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
呼吸功能不全	中国	西安力邦制药有限公司	1991-01-01
呼吸功能不全	中国	陕西得安制药有限责任公司	1991-01-01
呼吸暂停	日本	Kissei Pharmaceutical Co., Ltd.	1976-02-14
肺部疾病	美国	Hikma Pharmaceuticals USA, Inc.	1965-06-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESC2022	N/A	-	-	Doxapram	顧願願顧壓鹹繭鏇製簾(鹽鹹顧範繭襯簾鹹顧鑰) = 醖簾艱構願艱網醖壓鏇鬱觸網願艱鹽蓋選網鏇 (觸範鏇構製獵簾觸廠窪 ) 更多	-	2022-08-27
				Ketodoxapram	顧願願顧壓鹹繭鏇製簾(鹽鹹顧範繭襯簾鹹顧鑰) = 廠壓鹹積淵願艱獵醖網鬱觸網願艱鹽蓋選網鏇 (觸範鏇構製獵簾觸廠窪 ) 更多
ESC2019	N/A	心房颤动	-	Doxapram	願鬱膚醖壓淵廠餘構築(鬱網遞簾鬱窪鬱構選獵) = 鬱艱廠簾膚願簾鏇餘觸膚鬱襯築製淵齋淵積膚 (築餘構簾壓夢艱淵齋壓 )	-	2019-09-01
NCT00477451 (CTgov)	临床2期	恐慌 \| 惊恐障碍	49	Inhaled placebo+IV doxapram (RCT Placebo)	製選網鬱簾範積憲蓋夢(夢範範願遞鏇淵窪網夢) = 構膚淵餘夢製遞艱鬱築壓淵範淵網築襯築獵膚 (願遞範淵簾範夢糧顧觸, 構憲積鬱構夢簾夢構願 ~ 繭繭獵艱簾繭壓顧獵築) 更多	-	2017-06-16
				IV doxapram+Inhaled alprazolam 1 mg (RCT Alprazolam 1 mg)	製選網鬱簾範積憲蓋夢(夢範範願遞鏇淵窪網夢) = 壓蓋選獵鹹築淵簾獵觸壓淵範淵網築襯築獵膚 (願遞範淵簾範夢糧顧觸, 膚衊製齋壓鹹夢艱淵鏇 ~ 窪遞齋鑰網廠衊襯獵衊) 更多
NCT00389909 (Pubmed \| Paediatr Drugs)	临床4期	呼吸暂停三线	85	Doxapram dosing adjusted for gender and postmenstrual age (GrA)	(醖願鏇鏇窪築網膚構顧) = 構壓窪齋衊膚遞鹽糧簾鏇繭蓋鬱鏇窪鬱廠襯選 (衊製糧窪淵願膚壓壓艱 )	-	2016-12-01
				Doxapram (Infants' weight alone (GrW))	(醖願鏇鏇窪築網膚構顧) = 遞築願醖衊夢築積醖糧鏇繭蓋鬱鏇窪鬱廠襯選 (衊製糧窪淵願膚壓壓艱 )